Global Information Lookup Global Information

Angiokinase inhibitors information


Angiokinase inhibitors are a new therapeutic target for the management of cancer. They inhibit tumour angiogenesis, one of the key processes leading to invasion and metastasis of solid tumours, by targeting receptor tyrosine kinases.[1] Examples include nintedanib (BIBF 1120), afatinib (BIBW 2992) and motesanib (AMG 706).

  1. ^ Hilberg, F.; Roth, G. J.; Krssak, M.; Kautschitsch, S.; Sommergruber, W.; Tontsch-Grunt, U.; Garin-Chesa, P.; Bader, G.; et al. (2008). "BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy". Cancer Research. 68 (12): 4774–82. doi:10.1158/0008-5472.CAN-07-6307. PMID 18559524.

and 5 Related for: Angiokinase inhibitors information

Request time (Page generated in 0.7675 seconds.)

Angiokinase inhibitors

Last Update:

Angiokinase inhibitors are a new therapeutic target for the management of cancer. They inhibit tumour angiogenesis, one of the key processes leading to...

Word Count : 1445

Nintedanib

Last Update:

Meel JC, Roth GJ (2004). "BIBF1120 a novel, small molecule triple angiokinase inhibitor: profiling as a clinical candidate for cancer therapy". European...

Word Count : 3010

Boehringer Ingelheim

Last Update:

Alzheimer's. The company sold the rights to Faldaprevir, a HCV protease inhibitor to Trek Therapeutics. In July 2016, the company sold the commercialisation...

Word Count : 3271

Idiopathic pulmonary fibrosis

Last Update:

mild-to-moderate impairment in lung function". Nintedanib is a triple angiokinase inhibitor that targets receptor tyrosine kinases involved in the regulation...

Word Count : 7916

Motesanib

Last Update:

Company. It is an orally administered small molecule belonging to angiokinase inhibitor class which acts as an antagonist of VEGF receptors, platelet-derived...

Word Count : 956
PDF Search Engine © AllGlobal.net